# BioClaw Uploaded JSON - Harsh Grading

Source: GPT-5.5 Thinking Extended harsh grading of the uploaded BioClaw JSON
output against the BioClaw 24-task rubric. This was not author-scored.

Reported harsh score: 42/48 = 87.5%.

The grading note does not give credit for wrong IDs, bad counts, or dataset
metadata mismatches. The remaining serious problems are T10 and T11. The
remaining partial-credit problems are T03 and T09.

| Task | Score | Rationale |
|------|------:|-----------|
| T01 | 2 | Correct TP53 / P04637 / Homo sapiens. |
| T02 | 2 | Correct KRAS, 100% identity. |
| T03 | 1 | Pathogenic classification and relevant conditions are correct, but the ClinVar variant ID is wrong. Expected around VCV000017661, not VCV000013323.30. |
| T04 | 2 | Correct EGFR GRCh38 coordinates within tolerance. |
| T05 | 2 | Count is acceptable and at least 3 correct EGFR drugs are listed. |
| T06 | 2 | Correct Imatinib formula, molecular weight, and SMILES. |
| T07 | 2 | Melanoma is #1 and 3 scored BRAF-associated diseases are listed. |
| T08 | 2 | Lapatinib and afatinib are valid EGFR/HER2 dual inhibitors with indications. |
| T09 | 1 | Count is acceptable, but PMID 35189910 is not a good most-recent 2023-2024 PMID under the rubric. |
| T10 | 0 | Count 15 is too low; benchmark expects/accepts >30 recruiting U.S. TNBC trials. |
| T11 | 0 | Regrade needed. Original GPT-5.5 Thinking Extended grading marked this failed under an older incorrect rubric. The answer reported pDC influenza, human, 10 samples, which matches the later NCBI GEO correction; raw output should be regraded before final C4 scoring. |
| T12 | 2 | Correct journal and citation count above threshold. |
| T13 | 2 | Strong CD8+ cytotoxic T-cell marker list. |
| T14 | 2 | 5 plausible COVID DEGs with log2FC and adjusted p-values. |
| T15 | 2 | p53 signaling and cell cycle are both present with adjusted p-values. |
| T16 | 2 | AT2 plus secretory/goblet/club cells with DOI evidence. |
| T17 | 2 | EGFR AlphaFold pLDDT and structure URL included. |
| T18 | 2 | 5 plausible TP53 partners with high scores. |
| T19 | 2 | Valid CDK2 inhibitor complex, resolution <2.0 Angstrom, ligand named. |
| T20 | 2 | 5 correct EGFR phosphorylation sites. |
| T21 | 2 | Gene count is accepted; KEGG gene IDs are acceptable, though symbols would be better. |
| T22 | 2 | Correct top-level Reactome pathway and stable ID. |
| T23 | 2 | EGFR and TP53 are in the top 3 with degree values. |
| T24 | 2 | Count >10 and 5 BRCA1 biological-process GO terms with IDs. |
